These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9918732)

  • 1. Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I.
    Hall H; Halldin C; Guilloteau D; Chalon S; Emond P; Besnard J; Farde L; Sedvall G
    Neuroimage; 1999 Jan; 9(1):108-16. PubMed ID: 9918732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters.
    Goodman MM; Kilts CD; Keil R; Shi B; Martarello L; Xing D; Votaw J; Ely TD; Lambert P; Owens MJ; Camp VM; Malveaux E; Hoffman JM
    Nucl Med Biol; 2000 Jan; 27(1):1-12. PubMed ID: 10755640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells.
    Page G; Chalon S; Emond P; Maloteaux JM; Hermans E
    Neurochem Int; 2002 Feb; 40(2):105-13. PubMed ID: 11738476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain.
    Halldin C; Erixon-Lindroth N; Pauli S; Chou YH; Okubo Y; Karlsson P; Lundkvist C; Olsson H; Guilloteau D; Emond P; Farde L
    Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1220-30. PubMed ID: 12811422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter.
    Emond P; Garreau L; Chalon S; Boazi M; Caillet M; Bricard J; Frangin Y; Mauclaire L; Besnard JC; Guilloteau D
    J Med Chem; 1997 Apr; 40(9):1366-72. PubMed ID: 9135033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [125I] beta-CIT-FE and [125I] beta-CIT-FP are superior to [125I] beta-CIT for dopamine transporter visualization: autoradiographic evaluation in the human brain.
    Günther I; Hall H; Halldin C; Swahn CG; Farde L; Sedvall G
    Nucl Med Biol; 1997 Oct; 24(7):629-34. PubMed ID: 9352533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
    Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
    Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I.
    Ziebell M; Holm-Hansen S; Thomsen G; Wagner A; Jensen P; Pinborg LH; Knudsen GM
    J Nucl Med; 2010 Dec; 51(12):1885-91. PubMed ID: 21078806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging.
    Kuikka JT; Baulieu JL; Hiltunen J; Halldin C; Bergström KA; Farde L; Emond P; Chalon S; Yu M; Nikula T; Laitinen T; Karhu J; Tupala E; Hallikainen T; Kolehmainen V; Mauclaire L; Maziere B; Tiihonen J; Guilloteau D
    Eur J Nucl Med; 1998 May; 25(5):531-4. PubMed ID: 9575250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
    Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
    J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altropane, a SPECT or PET imaging probe for dopamine neurons: II. Distribution to dopamine-rich regions of primate brain.
    Madras BK; Gracz LM; Meltzer PC; Liang AY; Elmaleh DR; Kaufman MJ; Fischman AJ
    Synapse; 1998 Jun; 29(2):105-15. PubMed ID: 9593101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of the striatal dopamine transporter density and heterogeneity in type 1 alcoholics using human whole hemisphere autoradiography.
    Tupala E; Kuikka JT; Hall H; Bergström K; Särkioja T; Räsänen P; Mantere T; Hiltunen J; Vepsäläinen J; Tiihonen J
    Neuroimage; 2001 Jul; 14(1 Pt 1):87-94. PubMed ID: 11525341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-(3-lodoprop-2E-enyl)-2beta-carbomethoxy-3beta-(3',4'-dichloro phenyl)nortropane (beta-CDIT), a tropane derivative: pharmacological characterization as a specific ligand for the dopamine transporter in the rodent brain.
    Garreau L; Emond P; Belzung C; Guilloteau D; Frangin Y; Besnard JC; Chalon S
    J Pharmacol Exp Ther; 1997 Jul; 282(1):467-74. PubMed ID: 9223589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
    Poyot T; Condé F; Grégoire MC; Frouin V; Coulon C; Fuseau C; Hinnen F; Dollé F; Hantraye P; Bottlaender M
    J Cereb Blood Flow Metab; 2001 Jul; 21(7):782-92. PubMed ID: 11435790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
    Prunier C; Payoux P; Guilloteau D; Chalon S; Giraudeau B; Majorel C; Tafani M; Bezard E; Esquerré JP; Baulieu JL
    J Nucl Med; 2003 May; 44(5):663-70. PubMed ID: 12732666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter.
    Emond P; Guilloteau D; Chalon S
    CNS Neurosci Ther; 2008; 14(1):47-64. PubMed ID: 18482099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand.
    Varrone A; Steiger C; Schou M; Takano A; Finnema SJ; Guilloteau D; Gulyás B; Halldin C
    Synapse; 2009 Oct; 63(10):871-80. PubMed ID: 19562698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-m ethylph enyl)nortropane (PE2I).
    Guilloteau D; Emond P; Baulieu JL; Garreau L; Frangin Y; Pourcelot L; Mauclaire L; Besnard JC; Chalon S
    Nucl Med Biol; 1998 May; 25(4):331-7. PubMed ID: 9639293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo characterisation of nor-beta-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain.
    Bergström KA; Halldin C; Hall H; Lundkvist C; Ginovart N; Swahn CG; Farde L
    Eur J Nucl Med; 1997 Jun; 24(6):596-601. PubMed ID: 9169564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects.
    Kuikka JT; Tupala E; Bergström KA; Hiltunen J; Tiihonen J
    Eur J Nucl Med; 1999 Nov; 26(11):1486-8. PubMed ID: 10552092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.